EU Regulators Say Charlotte's Web Hemp CBD Safety "Cannot Be Established" - So Why Is It Entering Medicare?

That conclusion was not based on politics. It was based on data.

According to EFSA, critical gaps included:

• Significant portions of the product remaining uncharacterized

• Lack of reliable toxicological studies on the actual material

• Absence of human clinical data

• Unknown allergenicity and long-term safety profile

The agency's bottom line was clear:

The safety of the product could not be determined.

Meanwhile in the United States

At nearly the same time, the Centers for Medicare & Medicaid Services (CMS) launched the Substance Access Beneficiary Engagement Incentive (BEI) program.

The initiative allows participating healthcare providers to discuss and furnish certain hemp, marijuana derived cannabinoid products to Medicare beneficiaries under Innovation Center authority.

Unlike traditional drug pathways, the BEI program does not require approval from the U.S. Food and Drug Administration.

That distinction is central to a federal lawsuit now pending:

Smart Approaches to Marijuana (SAM), et al. v. Robert F. Kennedy Jr., et al.

Case No. 1:26-cv-01081 (U.S. District Court for the District of Columbia)

The Scientific Gap

Under the FDA framework, products intended for therapeutic use typically undergo:

• Controlled clinical trials

• Dose standardization

• Safety and toxicology evaluation

• Manufacturing and stability validation

The BEI program operates outside that structure.

While CMS has described the initiative as an innovation model, critics argue it effectively introduces products into federally funded care environments before those scientific benchmarks are met.

Why This Matters for Seniors

Medicare beneficiaries represent one of the most medically complex populations in the healthcare system.

Many patients:

• Take multiple medications (polypharmacy)

• Have chronic conditions

• Are more vulnerable to drug interactions

Cannabinoid compounds, including THC, are known to interact with metabolic pathways such as CYP450 enzymes, which are involved in processing many common medications.

Without controlled studies in this population, the full safety profile remains uncertain.

Rapid Supply Chain Expansion

At the same time the program launched, several companies publicly announced positioning within the emerging healthcare supply chain:

• Charlotte's Web highlighted alignment with CMS guidance

• Cornbread Hemp announced institutional distribution through a national group purchasing organization

These developments signal rapid commercialization of a category that has not undergone FDA drug approval review.

A Regulatory Tension

The situation creates a notable contradiction:

• International regulators say safety cannot be established

• The FDA has not approved these products as medicines

• Yet a federal healthcare program is enabling access within Medicare-linked systems

That tension is now at the center of federal litigation.

What the Court Will Decide

In SAM v. Kennedy (1:26-cv-01081), the court is evaluating whether CMS exceeded its statutory authority by introducing cannabinoid furnishing pathways without:

• Formal rulemaking

• Public notice and comment

• FDA validation standards

A ruling is expected to determine whether the program:

• Proceeds as implemented

• Is narrowed or modified

• Or is halted pending further review

The Core Question

This debate ultimately comes down to a fundamental issue in healthcare policy:

Should access to therapeutic products come before scientific validation-

or should science remain the gatekeeper?

Closing Perspective

The EFSA conclusion does not ban CBD products.

But it does highlight a critical reality:

The scientific evidence needed to establish safety is still incomplete.

As federal policy evolves, the question is not whether innovation should occur-

but whether it should occur before the science is fully understood,

particularly for the nation's most vulnerable patients.

CONTACT:

Madison Hisey